Menu ×

HEALTHCARE & PHARMACEUTICAL

Vertebrobasilar Artery Syndrome Treatment Market Segmentation by Diagnosis {Magnetic Resonance Angiography (MRA), MRI, Echocardiogram (ECG), and Others}; by Treatment (Surgery, and Medication); and by Distribution Channel (Hospital, Specialty Clinic, Pharmacies, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Vertebrobasilar Artery Syndrome Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • August 3, 2021: Sanofi-aventis Groupe announced the acquisition of Translate Bio to expand its portfolio in the production of therapeutics.

Global Vertebrobasilar Artery Syndrome Treatment Market Highlights over 2022 – 2030

The global vertebrobasilar artery syndrome treatment market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the degrading lifestyle practices amongst the global population, such as, smoking, lack of physical activities, high-cholesterol diet and others. Vertebrobasilar arteries are the arteries located at the back of the brain, which supply oxygen to the posterior of the brain. These arteries get blocked due to cholesterol buildup, which limits or blocks the blood supply to the brain, causing vertebrobasilar artery syndrome. This can be treated and controlled by changing lifestyle, combined with medications. However, bypass surgery is required for serious cases. Age plays a major role in vertebrobasilar artery syndrome owing to the degenerative conditions of the body, and it is common in individual above the age of 50 years. Rising geriatric population of the world is estimated to boost the market growth. According to the data by the World Bank, the global population above 64 years crossed 722.133 million in 2020.

Vertebrobasilar Artery Syndrome Treatment Market Graph

The market is bifurcated by treatment into surgery and medication, out of which, the medication segment is anticipated to hold the leading revenue share in the global vertebrobasilar artery syndrome treatment market over the forecast period as drugs are preferred by doctors to treat the vertebrobasilar artery syndrome, owing to the less risk, lower cost, and easy administration of medicines over surgery. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Vertebrobasilar Artery Syndrome Treatment Market Regional Synopsis

On the basis of geographical analysis, the global vertebrobasilar artery syndrome treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is forecasted to witness substantial growth during the forecast period on the back of emergent healthcare infrastructure and improvement in medical facilities in developing nations, such as, India, China, Bangladesh, Singapore, and Indonesia, among others. In addition to this, the high geriatric population in the APAC region is estimated to boost the market growth. According to the data by the World Bank, 6.574% of the total population of India aged above 65 years, in 2020, while the same value for China is 11.96% of the total population. Moreover, favorable market policies in these countries, attracting international investment, along with the growing disposable income are estimated to boost the market growth.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of high healthcare expenditure, presence of major pharmaceutical companies, and increasing expenditure in R&D activities. According to the statistics by the World Bank, in 2018, North America spent USD 10,050.516 for the healthcare of every individual. The total healthcare expenditure accounted for 16.415% of the total GDP of North America. 

Vertebrobasilar Artery Syndrome Treatment Market Share Graph

The global vertebrobasilar artery syndrome treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global vertebrobasilar artery syndrome treatment market includes the following segments:

By Diagnosis

  • Magnetic Resonance Angiography (MRA)
  • Echocardiogram (ECG) 
  • Others

By Treatment

  • Surgery
  • Medication

By Distribution Channel

  • Hospital
  • Specialty Clinic
  • Pharmacies
  • Others

Growth Drivers

  • Poor Lifestyle of the Population
  • Growing Geriatric Population across the Globe

Challenges

  • Lack of Healthcare Awareness amongst People

Top Featured Companies Dominating the Market

  • Abbott Laboratories
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Merck & Co., Inc.
  • Siemens Healthcare GmbH
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services, Inc.
  • Baxter International, Inc.
  • Novartis AG
  • Sanofi-aventis Groupe
  • AbbVie Inc.
  • Pfizer Inc.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved